Literature DB >> 22772564

Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Thomas A Wynn1, Thirumalai R Ramalingam.   

Abstract

Fibrosis is a pathological feature of most chronic inflammatory diseases. Fibrosis, or scarring, is defined by the accumulation of excess extracellular matrix components. If highly progressive, the fibrotic process eventually leads to organ malfunction and death. Fibrosis affects nearly every tissue in the body. Here we discuss how key components of the innate and adaptive immune response contribute to the pathogenesis of fibrosis. We also describe how cell-intrinsic changes in important structural cells can perpetuate the fibrotic response by regulating the differentiation, recruitment, proliferation and activation of extracellular matrix-producing myofibroblasts. Finally, we highlight some of the key mechanisms and pathways of fibrosis that are being targeted as potential therapies for a variety of important human diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772564      PMCID: PMC3405917          DOI: 10.1038/nm.2807

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  181 in total

1.  Telomerase regulation of myofibroblast differentiation.

Authors:  Tianju Liu; Biao Hu; Myoung Ja Chung; Matt Ullenbruch; Hong Jin; Sem H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

2.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Authors:  Ganesh Raghu; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Roland M du Bois; Joseph A Lasky; Michiel Thomeer; James P Utz; Rezaul K Khandker; Lawrence McDermott; Saeed Fatenejad
Journal:  Am J Respir Crit Care Med       Date:  2008-07-31       Impact factor: 21.405

3.  Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis.

Authors:  Melanie L Dart; Ewa Jankowska-Gan; Guorui Huang; Drew A Roenneburg; Melissa R Keller; Jose R Torrealba; Aaron Rhoads; Byoungjae Kim; Joseph L Bobadilla; Lynn D Haynes; David S Wilkes; William J Burlingham; Daniel S Greenspan
Journal:  Circ Res       Date:  2010-09-02       Impact factor: 17.367

4.  New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis.

Authors:  Lei Sun; Marisa C Louie; Kevin M Vannella; Carol A Wilke; Ann Marie LeVine; Bethany B Moore; Thomas P Shanley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-03       Impact factor: 5.464

5.  Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis.

Authors:  P F Piguet; M A Collart; G E Grau; A P Sappino; P Vassalli
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

6.  Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation.

Authors:  L Fan; H L Benson; R Vittal; E A Mickler; R Presson; A Jo Fisher; O W Cummings; K M Heidler; M R Keller; W J Burlingham; D S Wilkes
Journal:  Am J Transplant       Date:  2011-04-19       Impact factor: 8.086

7.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis.

Authors:  Won-Il Jeong; Ogyi Park; Bin Gao
Journal:  Gastroenterology       Date:  2007-09-29       Impact factor: 22.682

Review 9.  The role of IL-1 in the pathogenesis of heart disease.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

10.  Activation of WNT/β-catenin signaling in pulmonary fibroblasts by TGF-β₁ is increased in chronic obstructive pulmonary disease.

Authors:  Hoeke A Baarsma; Anita I R Spanjer; Gertruud Haitsma; Lilian H J M Engelbertink; Herman Meurs; Marnix R Jonker; Wim Timens; Dirkje S Postma; Huib A M Kerstjens; Reinoud Gosens
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

View more
  1070 in total

1.  TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice.

Authors:  Shaik O Rahaman; Lisa M Grove; Sailaja Paruchuri; Brian D Southern; Susamma Abraham; Kathryn A Niese; Rachel G Scheraga; Sudakshina Ghosh; Charles K Thodeti; David X Zhang; Magdalene M Moran; William P Schilling; Daniel J Tschumperlin; Mitchell A Olman
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 3.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

4.  Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study.

Authors:  Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djoussé; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Siscovick; Russell P Tracy; Susan J Zieman; Kenneth J Mukamal
Journal:  Am J Epidemiol       Date:  2014-04-25       Impact factor: 4.897

Review 5.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

6.  Interleukin 1 (IL-1)- and IL-23-mediated expansion of filarial antigen-specific Th17 and Th22 cells in filarial lymphedema.

Authors:  R Anuradha; P Jovvian George; V Chandrasekaran; P Paul Kumaran; Thomas B Nutman; Subash Babu
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

Review 7.  Role of Platelet-Derived Transforming Growth Factor-β1 and Reactive Oxygen Species in Radiation-Induced Organ Fibrosis.

Authors:  Jasimuddin Ahamed; Jeffrey Laurence
Journal:  Antioxid Redox Signal       Date:  2017-07-05       Impact factor: 8.401

8.  Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.

Authors:  Jason C Gardenier; Geoffrey E Hespe; Raghu P Kataru; Ira L Savetsky; Jeremy S Torrisi; Gabriela D García Nores; Joseph J Dayan; David Chang; Jamie Zampell; Inés Martínez-Corral; Sagrario Ortega; Babak J Mehrara
Journal:  JCI Insight       Date:  2016-09-22

Review 9.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

10.  EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.

Authors:  Sang-A Park; Min-Jin Kim; So-Yeon Park; Jung-Shin Kim; Seon-Joo Lee; Hyun Ae Woo; Dae-Kee Kim; Jeong-Seok Nam; Yhun Yhong Sheen
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.